Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components.
about
Hib Vaccines: Past, Present, and Future PerspectivesFactors contributing to the immunogenicity of meningococcal conjugate vaccinesReduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection.On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial.Heavy-chain isotype patterns of human antibody-secreting cells induced by Haemophilus influenzae type b conjugate vaccines in relation to age and preimmunity.Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccinesMucosal immunogenicity of polysaccharides conjugated to a peptide or multiple-antigen peptide containing T- and B-cell epitopes.Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate.Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier proteinRecombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.
P2860
Q26767144-ACE8E125-1F89-4CC3-AA5F-7AB57C6F5368Q28828544-4F32B12D-20A6-4EF4-8EC9-8B0BB00DDBEEQ33753799-85AF0DFC-9298-4277-870D-3A20DB334402Q33877194-76DE83A9-35A3-41C0-A97C-F6A20E85A2E6Q34131154-43EBE138-7C30-4B22-AA24-A513714B5C01Q34160588-D80DB6AD-37EA-495E-A562-3D5EA8153E7AQ34170021-8AD0266B-34A6-4CA3-952B-96FDDDB21BDBQ34235531-5DCC93FC-391A-43B6-9A1A-1B8FDC0B277BQ34291076-CDB2B466-1F5B-4526-A6BF-551B1A7BEAADQ34531792-DB59CE6C-5806-49B1-869E-4AD7E7A57A11Q35393344-F754E4C3-4E8E-4B0E-A1CF-C0945B088920Q35423315-0CB9E701-FCC5-46B0-AECA-3EC56820F603Q35546011-28C0F03C-2CBE-4459-9888-47C9173CC572Q35770637-661355C7-CD1C-41E3-AE5B-B7B703E923AAQ36746962-1F0C0AA7-A27A-47EF-8384-4891C1D5A545Q37169092-0F210DB0-5202-4701-9ABC-A849EE8D2296Q40056277-0F54AF26-8612-4427-950B-2322A1FD645AQ41812746-86E3125E-85F3-4CDF-8725-BD3CF6B4F76A
P2860
Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Non-epitope-specific suppressi ...... ation with vaccine components.
@en
type
label
Non-epitope-specific suppressi ...... ation with vaccine components.
@en
prefLabel
Non-epitope-specific suppressi ...... ation with vaccine components.
@en
P2093
P2860
P1476
Non-epitope-specific suppressi ...... zation with vaccine components
@en
P2093
P2860
P304
P407
P577
1993-02-01T00:00:00Z